ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
SCOTTSDALE, Ariz., July 29 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on ora...
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
DALLAS, July 23 /PRNewswire-FirstCall/ -- AC C E S S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , announced today that its European partner, SpePharm , is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing...
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
of alternative drug delivery systems, today reported positive results from a
Phase 2A study of its oral
insulin capsule, ORMD-0801, on type 1 diabetic
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral...
Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
SAN DIEGO, June 29 /PRNewswire/ -- Palkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) enzyme system. In February 2008, Palkion was founded ...
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
Therapeutic for IBD with Novel Mode of Action
MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral
Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical tria...
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral
B-cell chronic lymphocytic leukemia (CLL) drug. Ofort...
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that final survival data from a randomized Phase 2 trial evaluating OGX-011 in combination with docetaxel versus docetaxel alone as first-line chemotherapy in patients with ...
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosc...
Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
HAMILTON, Bermuda, March 27 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX ) announced today that its affiliate, Warner Chilcott Company Inc. has submitted a New Drug Application for WC 3016, a low-dose oral
contraceptive, to the U.S. Food and Drug Administration.
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Findings Support Development for Chronic Pain Indications
LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that oral
administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy m...
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity
SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral
presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco...
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that it has begun patient enrollment
in a large Phase ...
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Duramed to Launch First Lower-Dose, Extended-Cycle Oral
for the Prevention of Pregnancy
MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals,
Inc. (NYSE: BRL ) today announced that the U.S. Food and Drug Administration
(FDA) has approved its subsidiary Durame...
Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
- Using proprietary platform, company develops first orally-administered vaccine to protect against avian influenza in a large-animal model -
SAN FRANCISCO, Oct. 24 /PRNewswire/ -- Vaxart Inc., a biotechnology
company focused on the development of oral
vaccines, today announced
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics,
Inc. (Nasdaq: TPTX ) today announced it initiated dosing of the first cohort
of subjects in a Phase I multiple dose clinical trial of NGX426, the oral
prodrug of its most advanced product candidate, tezampanel. The trial is
NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
SOPHIA ANTIPOLIS, France, September 23 /PRNewswire-FirstCall/ -- NicOx
S.A. (Euronext Paris: COX) today announced it has signed an exclusive
agreement with Capsugel, the leading producer of two-piece capsules, for
the commercial manufacturing and global supply of naproxcinod capsules.
Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
Phase III Study to Explore the Effects of Oral
combination of Salmon Calcitonin and Eligen Delivery Technology on Knee
CEDAR KNOLLS, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pha...
Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
WELLESLEY HILLS, Mass., Sept. 9 /PRNewswire/ -- Joseph F. Finn, Jr.,
C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for
the benefit of creditors, announced today that all oral
intellectual property will be sold at a sealed bid auction on October 10,
Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
ORMD 0801 to be Tested on Type 2 Diabetic Volunteers
JERUSALEM, September 9 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
delivery systems, announced today the signing of an agreement with
ETI Karle Clinical Pvt...
New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
Solution Also Approved for Treatment-Experienced Adult Patients
RIDGEFIELD, Conn., June 24 /PRNewswire/ -- Boehringer Ingelheim
Pharmaceuticals, Inc. today announced that the U.S. Food and Drug
Administration (FDA) granted approval of Aptivus(R) (t...
Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
Company Also Completes FDA Submission for Removal of Clinical Hold
BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced that the Company has
received notice of allowances for two major patents from the European
Patent Office for i...
Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral
systems, announced today that it has been selected to display its abstract,
entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral
AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex
Therapeutics (a wholly-owned subsidiary of AVANT
Immunotherapeutics)(Nasdaq: AVAN ) announced today that its lead product
candidate, CDX-110, being developed for the treatment of Glioblastoma
Multiforme (GBM), will be the subject of...
PreViser and Oral Health Innovations Ltd Form UK Partnership to Provide Oral Health Scoring and Risk Analysis
MOUNT VERNON, Wash., May 20 /PRNewswire/ -- PreViser Corporation
( http://www.previser.com ), a Washington State-based provider of patented
oral disease and risk assessment technology to the dental profession,
announced today the finalization of a licensing agreement with Oral
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
Investigator to discuss assay built on VeraTag(TM) technology's ability to predict response to Herceptin(R)
SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM ) today announced that scientific
collaborators will present res...
Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule
Oramed is one of 60 Companies Selected to Participate at the "Facing Tomorrow" Conference Marking the Country's 60th Birthday
JERUSALEM, Israel, May 6 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP), a developer of oral
has been selected for the ...
Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
BOSTON, April 16 /PRNewswire/ -- Paratek Pharmaceuticals, Inc.
announced today that it has closed the second and final tranche of a $40
million private financing. As previously announced, Aisling Capital led the
financing, with additional participation by new investors, the D.E. Shaw
Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA
LINCOLN, NE, April 15 /PRNewswire/ - The acceptance of Peros' oral
delivery platform and vaccine facility by the USDA marks another
significant achievement by Benchmark Biolabs, a full service
biopharmaceutical product development firm.
Benchmark Biolabs designed, constructed and oversees th...
PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations
MONTREAL, April 8 /PRNewswire/ - The PerOs team is proud to announce
the USDA/CVB has granted PerOs an Establishment License for the production
of bacterins as well as an autogenous bacterin license utilizing its
delivery formulation methods (Oralject(TM)).
"The approval of our...
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Forms One of the Largest Sales Teams Promoting a 5-ASA Medicine
BASINGSTOKE, England and PHILADELPHIA, March 26 /PRNewswire-FirstCall/
-- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announced today a co-promotion agreement with
TAP Pharmaceutical Pr...
Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
BOSTON, March 11 /PRNewswire/ -- Replikins, Ltd. has announced
development of a chemically synthesized vaccine specific to a Taura
Syndrome virus structure based on its patented Replikins(TM) technology.
When the vaccine was administered orally to shrimp, 91% survived a
challenge by the lethal...
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
WELLESLEY HILLS, Mass., March 6 /PRNewswire/ -- Joseph F. Finn, Jr.,
CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced
today that the Office of Orphan Products Development of the Food and Drug
Administration (FDA) has granted Orphan Drug Designation for M40403 for the
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
- New Agreement Provides for Development and Promotion of OraQuick(R) HCV Test Outside the United States -
KENILWORTH, N.J., and BETHLEHEM, Pa., Feb. 11 /PRNewswire/ -- Schering-
Plough Corporation (NYSE: SGP ) and OraSure Technologies, Inc. (Nasdaq:
OSUR) today announced an...
Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
REINACH, Switzerland, January 15 /PRNewswire-FirstCall/ -- Arpida Ltd.
(SWX: ARPN) today announced that it has received authorisation from the
U.S. Food and Drug Administration (FDA) to conduct a Phase II
'intravenous-to-oral' switch trial with iclaprim in patients with
complicated Skin and Sk...
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
PRINCETON, N.J., Dec. 21 /PRNewswire/ -- Otsuka Pharmaceutical
Development & Commercialization, Inc. announced today that the U.S. Food
and Drug Administration has accepted a new drug application (NDA) for the
company's investigational oral
once-daily medication tolvaptan, a selective
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
- Ardea Biosciences, Inc. Presents Initial Data on RDEA119 at the 2007
AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics -
SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (Nasdaq: RDEA ), a company focused on the discovery and development of
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
BOULDER, Colo., Aug. 29 /PRNewswire-FirstCall/ -- Pharmion Corporation
(Nasdaq: PHRM ) today announced that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation for oral
Azacitidine in the
treatment of Myelodysplastic Syndromes (MDS). Fast Track programs are designe...
Kline Study: Better Brushing Habits Boost European Oral Care Sales
care in Europe expected to outpace overall growth in cosmetics and toiletries market -
LITTLE FALLS, N.J., Aug. 21 /PRNewswire/ -- The efforts of government
agencies and product marketers to convince Europeans of the importance of
care appears to have...